Details

Autor(en) / Beteiligte

• Khvalevsky, Elina Zorde
• Gabai, Racheli
• Rachmut, Itzhak Haim
• Horwitz, Elad
• Brunschwig, Zivia
• Orbach, Ariel
• Shemi, Adva
• Golan, Talia
• Domb, Abraham J.
• Yavin, Eylon
• Giladi, Hilla
• Rivkin, Ludmila
• Simerzin, Alina
• Eliakim, Rami
• Khalaileh, Abed
• Hubert, Ayala
• Lahav, Maor
• Kopelman, Yael
• Goldin, Eran
• Dancour, Alan
• Hants, Yael
• Arbel-Alon, Sagit
• Abramovitch, Rinat
• Shemi, Amotz
• Galun, Eithan

Titel

Mutant KRAS is a druggable target for pancreatic cancer

Ist Teil von

• Proceedings of the National Academy of Sciences - PNAS, 2013-12, Vol.110 (51), p.20723-20728

Ort / Verlag

United States: National Academy of Sciences

Erscheinungsjahr

2013

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet this challenge, we have developed a local prolonged siRNA delivery system (Local Drug EluteR, LODER) shedding siRNA against the mutated KRAS (siG12D LODER). The siG12D LODER was assessed for its structural, release, and delivery properties in vitro and in vivo. The effect of the siG12D LODER on tumor growth was assessed in s.c. and orthotopic mouse models. KRAS silencing effect was further assessed on the KRAS downstream signaling pathway. The LODER-encapsulated siRNA was stable and active in vivo for 155 d. Treatment of PDA cells with siG12D LODER resulted in a significant decrease in KRAS levels, leading to inhibition of proliferation and epithelial–mesenchymal transition. In vivo, siG12D LODER impeded the growth of human pancreatic tumor cells and prolonged mouse survival. We report a reproducible and safe delivery platform based on a miniature biodegradable polymeric matrix, for the controlled and prolonged delivery of siRNA. This technology provides the following advantages: (i) siRNA is protected from degradation; (ii) the siRNA is slowly released locally within the tumor for prolonged periods; and (iii) the siG12D LODER elicits a therapeutic effect, thereby demonstrating that mutated KRAS is indeed a druggable target.